G. Jeannin

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Pasi A. Jänne, Alice T. Shaw, José Rodrigues Pereira et al. · The Lancet Oncology · 2012 · 654 citations

Non-small-cell Lung Cancer, Medicine, Metronomic Therapy +7

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez, Julien Mazières, A. Lavolé et al. · Journal for ImmunoTherapy of Cancer · 2022 · 108 citations · Full text

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial

Jean-Louis Pujol, A. Lavolé, Élisabeth Quoix et al. · Annals of Oncology · 2015 · 95 citations · Full text

Ifct-0802 Trial, Medicine, Metronomic Therapy +7

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

Pasi A. Jänne, Ian C. P. Smith, Gael McWalter et al. · British Journal of Cancer · 2015 · 74 citations · Full text

1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez, Julien Mazières, A. Lavolé et al. · Annals of Oncology · 2020 · 56 citations

Neoadjuvant Durvalumab, Surgical Oncology, Medicine +10